NCT06658925View on ClinicalTrials.gov

Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)HSCTTyrosine Kinase Inhibitor
Interventions
DRUG

Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.

Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06658925 - Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL | Biotech Hunter | Biotech Hunter